ѱ̿Ǿǰȸ Ʈ
|
|
|
ڷ |
Ǿǰ Ը ù 20
- Ǿǰ 10.8%, ̿Ǿǰ 16.7% -
- ̿Ǿǰ 31.5% 2 -
ǰǾǰó(ó չ) Ǿǰ(̿Ǿǰ ) Ը 15 19 2,364 12.9% 21 7,256 ó 20 븦 Ѿ, ̿Ǿǰ 2 ó ߴٰ .
Ը : -+
̿Ǿǰ: ȭǾǰ ̳ ü Ḧ Ͽ Ǿǰ , ġ
Ǿǰ 16 18 8,061 15(16 9,696) 10.8% þ, `16 31 2,040(3 6,209) (29 4,726, 3 3,348) 5.9% Ͽ.
: 15 7,140(`12) 16 3,761(`13) 16 4,194(`14) 16 9,696(`15) 18 8,061(`16)
츮 Ǿǰ ֿƯ¡ Ǿǰ ֱ 5 Ǿǰ 弼 Ű Ÿ 1 ü, ǰ ؿ ̴.
̿Ǿǰ ó 2 Ͽ, 1 ϸ鼭 15 ̾ ڸ Ͽ.
......
|
|
|
աǰ ó Ϻ Ծ
1.
ݿϿ ա ǰ з οó ϰ Ÿ Ϻ ̺ ϰ
2. ֿ䳻
. աǰ ƴϳ ʰ з Һи ǰ з ż( 3, 7)
. ֱ ݿ աǰ з ߰( 4)
. ǰȸ ż( 14)...... |
|
|
ħ |
LMO ħ
LMO(Living Modified Organism, ںü) Ģ , ü ȹ ɻ翡 ħ̴. ........ |
|
ȯ
ڷ |
籹
츮 8 17 籹 Ǹ ̿ ̿ ڿ ( ABS) غ ñ ̴.
7 6 ʱ ȣڿ ̿ ȭ ' 籹 ' ֵǾ. ڿ α ߱, ε, īȭ, ̾Ḷ ڿ ַ ̿ϴ , Ϻ, ѱ 7 ڰ å ߴ..... |
|
|
|
û |
|
ǰ |
ӻ |
ܰ |
()彺 |
20170710 |
ߵ ̻ ܾȰ ָ ʿ ȯڸ ȿ Ȯϱ , ߴ, Ȱ, ٱ, 1/3 ӻ
|
1/3 |
ھ彺 |
ѱ() |
20170710 |
༺ Ǽȯ ȯڸ MK-8353 + Pembrolizumab ϴ 1b ӻ |
1 |
1. MK-8353,
2. Pembrolizumab |
ѱȭ() |
20170710 |
50 ̻ ο ŬνƮ ǽǸ ȿ, ༺ ϱ 3, , , ڴ ӻ |
3 |
PF-06425090 |
()ѱ |
20170707 |
ܵ ڿ 뷮 Ÿ Ulocuplumab (BMS-936564) 1/2, , |
1/2 |
BMS-936564 |
()Ʈ |
20170705 |
索 α˾ ȯڿ ALLO-ASC-DFU ȿ ϴ , ߴ, , ౺, ٱ 3 ӻ |
3 |
ALLO-ASC-DFU |
ѱν |
201707075 |
ħ ȯڿ, ָ (PD-L1 ü) + ƮŬ/-ŬŹ ϴ ȭп + ȭп ȿ ϴ 3 ӻ
|
3 |
ƼƮ(RO554-1267) |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
OMEPRAZOLE
NDA #209400 |
OMEPRAZOLE |
OTC ȯ |
DEXCEL PHARMA |
07/05/2017 |
ENDARI
NDA #208587 |
L-GLUTAMINE |
Ǵ |
EMMAUS MEDCL |
07/07/2017 |
|
|
|
|
|
|
|
|
Clinical.gov ̱ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03211416 |
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer |
Advanced Adult Hepatocellular Carcinoma|Child-Pugh Class A|Stage III Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma |
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Sorafenib Tosylate |
Roswell Park Cancer Institute
National Cancer Institute (NCI) |
Phase 1
Phase 2 |
NCT03211247 |
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age |
Peanut Allergy |
Biological: Viaskin Peanut 250 mcg
Biological: Viaskin Peanut 100 mcg
Biological: Placebo |
DBV Technologies |
Phase 3 |
NCT03211117 |
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
Drug: Docetaxel
Drug: Doxorubicin Hydrochloride
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Therapeutic Conventional Surgery |
Mayo Clinic
National Cancer Institute (NCI) |
Phase 2 |
NCT03210662 |
Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Non-Hodgkin Lymphoma |
Radiation: External Beam Radiotherapy (EBRT)
Drug: Pembrolizumab |
M.D. Anderson Cancer Center
Merck Sharp & Dohme Corp. |
Phase 2 |
|
|
|
Clinical.gov ߱ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03209219 |
Interferon 2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis |
Behçet Disease
Uveitis
|
Drug: Interferon Alfa-2A
Drug: Cyclosporine Pill |
Peking Union Medical College Hospital |
Phase 3 |
|
|
|
|
|
|
̿Ǿǰ 2 , 1 |
16 ̿Ǿǰ Ը 11.6% |
ѱ̿Ǿǰȸ(ǥ ֱ) ǰǾǰó ǥ 16 Ǿǰ ڷḦ Ͽ ̿Ǿǰ ӻ ǰȭܰ ֱ Ȳ ǥϿ. ǰǾǰó , ̿Ǿǰ Ը 15 1 6,406 11.6% 1 8,308 ̾. ̿Ǿǰ 16 2 79 15(1 7,209) 16.7% ũ Ͽ. 16 10 6,397(1 2,346) 15(8 924, 9,156) 31.5% Ͽ, 16 15(7 3,822, 8,353) 23.5% 16 9 1,139(1 576)̾.
ӻ
1 , 2
2
1 ǰ ø
ѱ̿Ǿǰȸ(ǥ ֱ) ̿Ǿǰ 翡 ȹ̴.....
|
|
̿IT÷ '17 ű ȳ |
̿IT÷ 2017 ű |
2017 Ͽ 12 ܿ Ʈ, εþ, Űź 3 ߰ Դϴ. ɰ ̿ Ź 帳ϴ. |
|
̿IT÷ ȳ |
2017 ֿ ǿ(̱, , ߱) ü 㰡 (2017 ÷ܹ̿Ǿǰ ؿ ̿IT÷ ) Ӱ ǽ Դϴ. û ٶϴ. |
'' ̶? |
̿Ǿǰ ؿ 㰡 ִ
1:1(ñ: Ƿ ü) |
|
|
Ͻô ü ȸ Ǵ ̿IT÷ Ȩ ̿IT÷ û ȮϽð,
̿Ǿǰ ؿ Ƿڼ ۼϽþ ̸(bpis@kobia.kr) ûϽñ ٶϴ.
ִ 5 ȭ, (ܰ躰) Ƿڰ մϴ. |
|
̿IT÷ () ٷΰ |
|
̿IT÷ ٷΰ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|